Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)

Phase 2

Completed

Conditions: Lung Cancer
Non Small Cell Lung Cancer

Interventions: Drug: erlotinib
Drug: Pemetrexed
Drug: Cisplatin
Procedure: Resection

First Posted Date: 2007-12-20

Last Posted Date: 2018-01-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT00577707

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: CP-751,871
Drug: Cisplatin
Drug: Gemcitabine
Drug: Pemetrexed

First Posted Date: 2007-11-19

Last Posted Date: 2013-03-21

Lead Sponsor: Pfizer

Target Recruit Count: 46

Registration Number: NCT00560573

Locations: 🇪🇸
Pfizer Investigational Site, Sevilla, Spain

A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: erlotinib

First Posted Date: 2007-10-29

Last Posted Date: 2013-02-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 247

Registration Number: NCT00550173

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

Performance Status During Treatment With Pemetrexed in Patients With NSCLC

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed

First Posted Date: 2007-10-05

Last Posted Date: 2011-03-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 542

Registration Number: NCT00540241

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Homburg, Germany

Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: pemetrexed
Drug: enzastaurin
Drug: placebo
Drug: cisplatin

First Posted Date: 2007-10-03

Last Posted Date: 2020-11-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 35

Registration Number: NCT00538681

Locations: 🇷🇴
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania

Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: enzastaurin
Drug: carboplatin
Drug: pemetrexed
Drug: bevacizumab
Drug: Placebo

First Posted Date: 2007-09-21

Last Posted Date: 2021-05-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 40

Registration Number: NCT00533429

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States

Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: placebo
Drug: enzastaurin
Drug: pemetrexed

First Posted Date: 2007-09-17

Last Posted Date: 2020-07-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 160

Registration Number: NCT00530621

Locations: 🇵🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto, Portugal

A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase

Phase 1

Completed

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: Lapatinib
Drug: Pemetrexed

First Posted Date: 2007-09-12

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT00528281

Locations: 🇬🇧
GSK Investigational Site, Newcastle upon Tyne, United Kingdom

Chemotherapy for Patients With Osteosarcoma

Phase 2

Completed

Conditions: Osteosarcoma

Interventions: Drug: Pemetrexed

First Posted Date: 2007-08-31

Last Posted Date: 2011-06-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 32

Registration Number: NCT00523419

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newcastle-Upon-Tyne, Tyneside, United Kingdom

A Study of Pemetrexed in Children With Recurrent Cancer

Phase 2

Completed

Conditions: Osteosarcoma
Medulloblastoma
Sarcoma, Ewing's
Neuroblastoma (Measurable Disease)
Neuroblastoma (Metaiodobenzylguanidine
Positive Evaluable)
Rhabdomyosarcoma
Ependymoma
Non-brainstem High-grade Glioma

Interventions: Drug: pemetrexed

First Posted Date: 2007-08-27

Last Posted Date: 2011-02-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 72

Registration Number: NCT00520936

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arcadia, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy